Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Hosted on MSN2mon
Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap and is also known for developing an antibody cocktail for COVID-19, called REGEN-COV. Companies valued at $10 billion or ...
Hosted on MSN10mon
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDAOdronextamab is an investigational bispecific monoclonal antibody designed to bind to a component of the T-cell receptor complex while binding and ... should benefit from Dupixent’s continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback